Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Total Liabilities
Everything the company owes to creditors and other parties.
Immuneering CorporationNASDAQ: IMRX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 93713.8% from a year ago
Total liabilities stood at $8.29B at the end of Q1 FY2026, up 93713.8% from a year earlier and up 61314.7% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.
Context
- Total liabilities amounted to 3.9% of total assets at the end of Q1 FY2026, down 13.6 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +93713.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 13.5M USD
- Year-over-year change
- +19.2%
- 4-year CAGR
- +5.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.5M | +19.2% |
| FY2024 | 2024-12-31 | 11.33M | -5.7% |
| FY2023 | 2023-12-31 | 12.01M | -4.1% |
| FY2022 | 2022-12-31 | 12.52M | +16.7% |
| FY2021 | 2021-12-31 | 10.72M | — |
Total Liabilities vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's Mar 2026 total liabilities of $8.29B is the highest of the 11 companies compared; the peer median is $45.47M.
- Its year-over-year change of +93713.8% is the highest of 11, against a peer median of -10.2%.
- Total liabilities amounts to 3.9% of total assets for IMRX, versus a peer median of 21.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.29B | +93713.8% | +2.6% | 3.9% | |
| Mar 2026 | $298.58M | -6.8% | -8.8% | 134.4% | |
| Mar 2026 | $198.12M | -13.7% | +53.9% | 63.0% | |
| Mar 2026 | $98.93M | -21.8% | +9.0% | 89.5% | |
| Mar 2026 | $64.66M | -6.6% | +21.7% | 19.3% | |
| Mar 2026 | $54.05M | -44.9% | -31.8% | 22.0% | |
| Mar 2026 | $36.9M | -48.7% | +38.5% | 15.7% | |
| Mar 2026 | $33.36M | +0.3% | -0.9% | 18.8% | |
| Mar 2026 | $33.03M | +0.8% | -9.0% | 51.4% | |
| Mar 2026 | $28.88M | +17.6% | -12.7% | 21.4% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -23.1% | 5.1% |
| Peer median (excluding IMRX) | $45.47M | -10.2% | -4.9% | 21.7% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74.89M | 72.64M | 59.41M | 36.14M | 128.65M |
| Short-term Investments | 74.31M | 32.89M | 26.26M | 0 | 44.19M |
| Net Receivables | 246.04K | 12.42K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 3.21M | 3.42M | 3.44M | 3.41M |
| Total Current Assets | 152.33M | 108.75M | 89.08M | 39.59M | 176.25M |
| Property, Plant & Equipment (Net) | 6.13M | 5.78M | 5.4M | 4.79M | 4.26M |
| Goodwill | 6.7M | 6.69M | 6.69M | 6.69M | 6.69M |
| Intangible Assets | 439K | 408.95K | 379.68K | 350.41K | 321.15K |
| Long-term Investments | 996.56K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 102.13K | 743.7K | 1.03M | 1.3M | 44.47M |
| Total Non-current Assets | 14.37M | 13.62M | 13.5M | 13.13M | 55.74M |
| Total Assets | 166.7M | 122.37M | 102.58M | 52.71M | 231.99M |
| Account Payables | 1.39M | 3.15M | 2.11M | 1.96M | 1.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.92M | 3.65M | 3.89M | 3.82M | 4.54M |
| Total Current Liabilities | 5.63M | 8.05M | 7.85M | 7.5M | 10.07M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.09M | 4.46M | 4.16M | 3.82M | 3.43M |
| Total Liabilities | 10.72M | 12.52M | 12.01M | 11.33M | 13.5M |
| Common Stock | 26.32K | 26.42K | 29.27K | 31.05K | 64.65K |
| Retained Earnings | (59.27M) | (109.79M) | (163.26M) | (224.3M) | (280.32M) |
| Accumulated OCI | (49.01K) | (30.12K) | (778) | 0 | 81.33K |
| Other Stockholders Equity | 0 | 0 | 0 | 1 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 155.98M | 109.85M | 90.58M | 41.39M | 218.48M |
| Total Debt | 5.36M | 4.84M | 4.46M | 4.16M | 3.82M |
| Net Debt | (69.52M) | (67.8M) | (54.94M) | (31.98M) | (124.82M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.